Charles River Laboratories International (CRL) Contributed to Madison Small Cap Fund’s Healthcare Outperformance
Madison Investments, an investment advisor, released its “Madison Small Cap Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. The Fund outperformed its small-cap benchmarks during the third quarter of 2026, despite a challenging environment for quality-focused investors as speculative AI-related stocks retreated, inflation remained persistent, and rising bond yields […] Madison Investments, an investment advisor, has revealed that the "Madison Small Cap Fund" outperformed its small-cap benchmarks in Q3 2026, despite a challenging environment for quality-focused investors due to falling AI-related stocks, inflation, and rising bond yields. The Fund's Class R6 shares declined 5.80%, compared with losses of 7.23% for the Russell 2000 and 6.37% for its benchmark. Technology was the strongest sector relative to the benchmark, with software stocks recovering from AI disruption and health care also rebounded due to core holdings. In its second-quarter 2026 investor letter, Madison highlighted stocks like Charles River Laboratories International, Inc. (CRL), which provides drug discovery, preclinical development, and safety assessment services to pharmaceutical, biotechnology, and medical device companies.
Published : 6 hours ago by Attiya Zainib in Business Health Finance
Madison Investments, an investment advisor, released its "Madison Small Cap Fund" Q3 2026 investor letter. A copy of the letter can be downloaded here. The Fund outperformed its small-cap benchmarks d... [2529 symbols]
